Open AccessConnection Domain Mutations During Antiretroviral Treatment Failure in Mali
Author(s) -
Almoustapha Issiaka Maïga,
Sudhir Penugonda,
D Katilé,
Fodié Diallo,
Djeneba Bocar Fofana,
Baiba Berzins,
Moussa Youssouffa Maiga,
Aliou Sylla,
H. A. Traoré,
AnneGeneviève Marcelin,
Vincent Cálvez,
A. Tounkara,
Nobel A. Bellosillo,
Robert L. Murphy,
Babafemi Taiwo
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31826a4b34
Subject(s) - etravirine , nevirapine , reverse transcriptase , biology , genetics , virology , population , human immunodeficiency virus (hiv) , mutation , phenotype , gene , medicine , antiretroviral therapy , polymerase chain reaction , viral load , environmental health
Mutations in the connection domain (CD) of reverse transcriptase have been implicated in reverse transcriptase inhibitor (RTI) resistance, but this is controversial and little is known in non-B subtype HIV-1. We determined CD mutations prevalence in a population infected predominantly with CRF02_AG and investigated associations with phenotypic RTI resistance. Detected CD mutations were G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), Y318F (2.1%), G333E (2.1%), and A360V (2.1%). Mutations were largely polymorphic and did not confer RTI resistance. The observed trend toward reduced likelihood of etravirine or nevirapine resistance in the presence of G335D should be investigated further.